At RJH Biosciences, we develop non-viral, polymer-based nucleic acid delivery systems designed for efficient transfection of primary and hard-to-transfect cells. Our platform enables robust delivery of a range of nucleic acids with consistent performance across diverse cell types and animal models, outperforming commercial comparators. Our biocompatible reagents enable safe modification of cells in culture, and does not alter the normal physiology in animal models.
Preserves Organ Health
RJH reagents are designed to prioritize safety at every dose administered in pre-clinical animal models, minimizing potential toxicity. (Control: sham-treated, RJH Reagent: Leu-Fect formulated with siRNA).
Maintains Blood Chemistrs
Serum chemistry profiles demonstrate that RJH reagent does not disrupt the key blood chemistry parameters in mice. Creatine kinase, total protein, and bilirubin remain within normal physiological ranges.
Compatible with Immune System
RJH reagents are developed for smooth performance without triggering cytokine induction and immune response. TNFα and IFNγ levels remain unaffected after administration of RJH reagents.
About RJH Biosciences
RJH Biosciences specializes in lipopolymer-based transfection reagents for efficient siRNA, mRNA, and DNA delivery across a wide range of biological systems. Our platforms are optimized for high-throughput screening, functional genomics, and RNA interference (RNAi) applications, enabling reliable gene modulation in cell lines, primary cells, and in vivo models.
With a focus on reproducibility, scalability, and low cytotoxicity, RJH supports researchers in accelerating drug discovery, target validation, and therapeutic development through customizable transfection solutions.
